França Esdras de Campos, Drummond Alexandre Fortes, Teixeira Karina Imaculada Rosa, Oliveira Ricardo Reis, Orlando Ricardo, Sinisterra Ruben Dario, Cortés Maria Esperanza
Restorative Dentistry Department, Dentistry Faculty, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
Orthodontics and Odontopediatric Department, Dentistry Faculty, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.
Int Dent J. 2025 Apr;75(2):1011-1020. doi: 10.1016/j.identj.2024.10.013. Epub 2024 Dec 4.
The majority of orthodontic patients present with plaquebiofilm and related manifestations in the early stages of active fixed orthodontic appliance use.
To evaluate the effects of a slow-delivery chlorhexidine:beta-cyclodextrin (Cx:β-Cd) gel compared with those of free Cx free formulations on clinical parameters in patients undergoing treatment with fixed orthodontic appliances.
Patients aged 12-18 years received prophylaxis and scaling and were randomised to treatment groups in a double-blinded manner. They were treated with Cx:β-Cd, Cx, or placebo gel for 15 or 30 days. Bleeding on probing and the visible plaque index were recorded, and gingival crevicular fluid samples were collected for the assessment of cytokine expression.
At 15 days, the Cx:β-Cd group exhibited significantly less BOP than did the Cx and control groups (P < 0.001; n = 116). At 15 days, notable decreases in tumour necrosis factor-α and interferon-γ expression, as well as a substantial increase in interleukin-10 expression, were observed in the Cx:β-Cd and Cx groups relative to the control group (P < 0.05). The molecular encapsulation gel resulted in greater saliva Cx concentrations than did the free Cx gel released concentrations of 800 ng g.
Cx:β-Cd gel is effective for the slow delivery of Cx, improving the gingival health of adolescents undergoing orthodontic treatment.
A single application of encapsulated Cx gel, was a more effective antiseptic than a free Cx application in fixed orthodontice appliance wearers.
大多数正畸患者在使用活动固定正畸矫治器的早期阶段会出现菌斑生物膜及相关表现。
评估缓释洗必泰：β - 环糊精（Cx:β - Cd）凝胶与游离洗必泰制剂相比，对接受固定正畸矫治器治疗患者临床参数的影响。
年龄在12 - 18岁的患者接受预防性洁治和龈上洁治，并以双盲方式随机分为治疗组。他们分别用Cx:β - Cd、Cx或安慰剂凝胶治疗15天或30天。记录探诊出血和可见菌斑指数，并收集龈沟液样本以评估细胞因子表达。
在15天时，Cx:β - Cd组的探诊出血明显少于Cx组和对照组（P < 0.001；n = 116）。在15天时，相对于对照组，Cx:β - Cd组和Cx组中肿瘤坏死因子 - α和干扰素 - γ表达显著降低，白细胞介素 - 10表达大幅增加（P < 0.05）。分子包封凝胶导致唾液中Cx浓度高于游离Cx凝胶释放浓度800 ng/g。
Cx:β - Cd凝胶可有效实现Cx的缓慢释放，改善正畸治疗青少年的牙龈健康。
在固定正畸矫治器佩戴者中，单次应用包封Cx凝胶比游离Cx应用是更有效的防腐剂。
